Navigation Links
Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension

Next Generation Renin Inhibitor to Continue Phase II Profiling in Diabetic Patients


BASEL/Switzerland and BRIDGEWATER NJ/USA, 28 June 2007-Speedel (SWX: SPPN) today announced that it has reached another significant milestone in the development of its family of renin inhibitors with the successful completion of a Phase IIa proof-of-concept clinical trial with SPP635 for the treatment of hypertension. Based on these positive results, the company is to continue developing SPP635 in Phase II in a special population of diabetic patients with mild-to-moderate hypertension. This compound is the first of a next generation of renin inhibitors following Speedel's lead product SPP100 (aliskiren, Tekturna/Rasilez[1]), which is partnered with Novartis and recently obtained US marketing approval from the FDA and a positive opinion from the CHMP in Europe[2]. SPP635 is the most advanced compound in the SPP600 series and is one of several new proprietary renin inhibitors invented by Speedel Experimenta, the company's late-stage research unit.

Phase IIa results demonstrate strong efficacy and good tolerability
The trial had a double-blind, placebo-controlled, randomised, parallel design and it evaluated patients treated with a single dosage level of SPP635 once-daily for 4 weeks. It studied the safety and efficacy of SPP635 in 35 male and female patients (20 patients receiving SPP635 and 15 receiving placebo) with mild-to-moderate hypertension by measuring office and ambulatory blood pressure[3].

SPP635 was safe and well tolerated over the 4 week period. There were no serious adverse events reported nor were there any clinically significant changes in laboratory safety parameters. Sitting systolic blood pressure was significantly reduced by 17.9 mmHg from 156.6±9.1 mmHg at baseline (mean ± SD) to 138.7±13.3 mmHg in the SPP635 treated group after 4 weeks (p<0.001). The placebo group remained unchanged (156.1&plu
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
3. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
4. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
9. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
10. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
11. Bentley Reports Positive Results with Nasulin Intranasal Insulin Spray at the American Diabetes Association Meeting

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Speedel Reports Successful SPP635 Phase IIa Trial Hypertension
(Date:11/9/2009)..., ROCKVILLE, Md., Nov. 9 OriGene T...of Technology in Sweden has adopted its VERIFY Tag...uman Protein Atlas program. This program is funded...s set up to explore the human proteome systematica...igh quality mono-specific antibodies in a high thr...
(Date:11/9/2009)..., POTOMAC FALLS, Va., Nov. 9 TessA...roarray-based applications, announces the launch o...ting of the mutations that underlie human heredita...ise in microarray-based resequencing with novel nu...sis software enables screening for all targeted mu...
(Date:11/9/2009)..., TOWN OF HEMPSTEAD, N.Y., Nov. 9 /PRNewswire/ --...lice officers and other rescue workers came togeth...ity. Merrick firefighter Brian McCauley was one of...o save his own life. ,, Only in his late 30s, M...undergone surgery and extensive chemotherapy treat...
Breaking Medicine Technology:Royal Institute of Technology Adopts OriGene Over-Expression Lysates in Human Proteome Atlas Program 2TessArae Delivers Lower Cost Option to Genetic Testing Market 2The SCOOTER Store Surprises 9/11 First Responder & Merrick Firefighter With Power Chair 2The SCOOTER Store Surprises 9/11 First Responder & Merrick Firefighter With Power Chair 3Pausing Hormone Therapy Doesnt Cut Mammogram Recalls 47850 1Pausing Hormone Therapy Doesnt Cut Mammogram Recalls 47850 2Synthetech Announces Fiscal 2009 Results 47845 1Synthetech Announces Fiscal 2009 Results 47845 2Synthetech Announces Fiscal 2009 Results 47845 3Synthetech Announces Fiscal 2009 Results 47845 4Synthetech Announces Fiscal 2009 Results 47845 5Synthetech Announces Fiscal 2009 Results 47845 6Consumer Watchdog Praises Insurance Commissioner Poizner for Health Insurance Rescission Rules Pans Schwarzenegger Administration for Failure to Regu 47842 1Consumer Watchdog Praises Insurance Commissioner Poizner for Health Insurance Rescission Rules Pans Schwarzenegger Administration for Failure to Regu 47842 2Consumer Watchdog Praises Insurance Commissioner Poizner for Health Insurance Rescission Rules Pans Schwarzenegger Administration for Failure to Regu 47842 3
... Potency and Slow Dissociation from HCV,Protease ,...ia COMTEX News,Network/ -- InterMune, Inc. (Nasdaq...e company,s Hepatitis C virus (HCV) NS3/4A,proteas... of the,Digestive Disease Week (DDW) meeting being...tudy (DDW abstract #M1816) examined,ITMN-191 poten...
...ATION WITH DIURETIC ACCEPTED FOR REVIEW BY,FDA- , ...07 -,Speedel (SWX: SPPN) today welcomed the signif...aliskiren, Tekturna/Rasliez[1]),presented by inves... Exposition of the American Society of Hypertensio... the favourable safety and,efficacy profile, as we...
Other Medicine Technology:InterMune Presents Research on ITMN-191 in Hepatitis C at Digestive,Disease Week Meeting 2InterMune Presents Research on ITMN-191 in Hepatitis C at Digestive,Disease Week Meeting 3InterMune Presents Research on ITMN-191 in Hepatitis C at Digestive,Disease Week Meeting 4InterMune Presents Research on ITMN-191 in Hepatitis C at Digestive,Disease Week Meeting 5New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 2New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 3New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 4New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 5New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 6New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 7New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 8New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 9New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 10New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 11
(Date:11/9/2009)...abbits implanted with new cells regained sexual fu...9 (HealthDay News) -- Researchers were able to res...es by growing new penile tissue in the lab and imp...an application is a ways off, researchers say the ...ectile dysfunction in men. , "We were able to s...
(Date:11/9/2009)... Course, to be Offered in ...sic Toolkit , Cambridge, ... of Physicians for Human Rights (PHR) first inspec...ghanistan , he realized he would need a team of ex...cumenting the site properly was a key first step i...
(Date:11/9/2009)..., March of Dimes Names 2010 National Ambassad...USNewswire/ -- Joshua Hoffman of Weston, Fla., was...ans that doctors could not say whether he would su...ar. Today, the 6-year-old was named March of Dimes...lanie Hoffman, recalls, "My first minutes of mothe...
(Date:11/9/2009)...tudy didn,t answer question of why this is so, how...s) -- After a lumpectomy, women with very dense br...he affected breast, a new study shows. , Breast... risk of developing breast cancer, and experts hav...sociated with an increased risk of cancer recurren...
(Date:11/9/2009)..., PITTSFIELD, Maine, Nov. 9 At ...nts in Maine are increasingly concerned about find...ompetitive Medicare option for 2010. ,, The Tod... (PPO) Medicare Advantage plan provides a cost-eff...edicare or a Medicare Supplement plan. People wit...
Breaking Medicine News(10 mins):Health News:Scientists Grow New Penile Tissue in the Lab 2Health News:Scientists Grow New Penile Tissue in the Lab 3Health News:Physicians for Human Rights Offers Training in Crime Scene Documentation 2Health News:Physicians for Human Rights Offers Training in Crime Scene Documentation 3Health News:Physicians for Human Rights Offers Training in Crime Scene Documentation 4Health News:Six-Year-Old Survivor Fights for Preemies Like Himself 2Health News:Six-Year-Old Survivor Fights for Preemies Like Himself 3Health News:Dense Breasts Raise Risk of Cancer Recurrence 2Health News:Dense Breasts Raise Risk of Cancer Recurrence 3Health News:Maine Residents With Medicare Searching for Affordable and Innovative Insurance Have Competitive Medicare Advantage Option 2
... Terri Milen of TEM Counseling LLC lau...terrimilen.com [Online Counseling via video/phone...] to clients in the comfort of their own home or o...which requires clients to make room for another ap...
...no sample traced back to Mexican farm, FDA announc...- Almost a week after uncovering the first big cl...lth officials announced Friday that tainted jalape...s grown in the United States, but warned consumers...
...o discuss second quarter financial results -, LAV... Inc. (TSX: DDS;,NASDAQ: DDSS) today announced tha... 8 at 8:30 a.m. (ET) to discuss its second quarter...o access the conference call by telephone, dial 41...
... cleaning products reduces lung function, increase...uly 25 (HealthDay News) -- A clean, fresh-smelling...ng on what type of cleaning and air freshening pro...called 1,4 dicholorobenzene (1,4 DCB), can reduce ...
...5 BeaconEquity.com announces the,availability of ...ors can view all of the daily trading notes for fr...y,s Trade Alerts include: DUSA Pharmaceuticals Inc...daq: AFFX ) and,Abaxis Inc. (Nasdaq: ABAX )., J...
...Marketing Exclusivity Begins -, CORONA, Calif., J..., a leading specialty pharmaceutical,company, anno...ercial,shipment of its Omeprazole Delayed-Release ...ting exclusivity for being the,first to file an AN...
Other Medicine News:Health News:Online Counseling and Life Coaching Practice Launches New Website 2Health News:Mexican Peppers ID'd as Salmonella Culprits 2Health News:Mexican Peppers ID'd as Salmonella Culprits 3Health News:Labopharm to host conference call Friday, August 8, 2008 at 8:30 A.M. (ET) 2Health News:Health Hazards in Household Cleaners Exposed 2Health News:Health Hazards in Household Cleaners Exposed 3Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 2Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 3Health News:Watson Launches Omeprazole Delayed-Release Capsules, 40MG 2
Liquichek Reticulocyte Control
Liquichek ToRCH Plus IgM Controls
Liquichek Seroconversion Panels
Amplichek CT/GC Controls
Medicine Products: